4-butyrolactone has been researched along with lapatinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baek, JM; Boulbes, D; Esteva, FJ; Gomez-Cabello, D; Hawke, DH; Hortobagyi, GN; Hung, MC; Jin, Q; Lee, MH; Wang, YN; Yeung, SC; Yuan, LX | 1 |
| Bessadóttir, M; Eccles, S; Gowan, S; Ogmundsdóttir, HM; Ögmundsdóttir, S; Skúladóttir, EÁ | 1 |
2 other study(ies) available for 4-butyrolactone and lapatinib
| Article | Year |
|---|---|
Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
Topics: 4-Butyrolactone; Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Fatty Acid Synthases; Female; Fluorescent Antibody Technique; Gene Expression; Humans; Lapatinib; Mass Spectrometry; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Neuregulin-1; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction | 2010 |
Effects of anti-proliferative lichen metabolite, protolichesterinic acid on fatty acid synthase, cell signalling and drug response in breast cancer cells.
Topics: 4-Butyrolactone; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Fatty Acid Synthases; Female; Humans; Lapatinib; Lichens; Molecular Structure; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2014 |